Connect with us


FDA Approves Beovu for Diabetic Macular Edema

It’s the second FDA-approved indication for the drug.




EAST HANOVER, NJ — Novartis announced that the U.S. Food and Drug Administration has approved Beovu for the treatment of diabetic macular edema.

The approval represents the second FDA-approved indication for Beovu (brolucizumab-dbll 6 milligrams), which was first approved for the treatment of wet age-related macular degeneration in 2019, according to a press release. Per the approved Beovu prescribing information, following the loading phase of five doses injected six weeks apart, patients should be treated once every eight to 12 weeks.

“The FDA approval of BEOVU in DME marks a significant milestone for US DME patients, many of whom are of working age and struggle with treatment adherence while juggling multiple doctor’s visits every month,” said Jill Hopkins, senior vice president and global development unit head, ophthalmology, Novartis.

Hopkins added: “This FDA approval follows the recent European Commission approval and allows more patients around the world to potentially benefit from this important medicine.”


Turn Patients Into Loyal Eyewear Shoppers

80% of patients are browsing eyewear online, are you influencing patients online before your competition? Join thousands of practices thriving with Optify, voted the #1 optical sales tool by EyeVote. Empower your opticians to save time, increase optical revenue, and maximize your EHR data and website with a seamless optical plug-in that keeps patients buying from YOU! Now through August 31st receive a $25 UberEats® gift card when you complete a 15 min demo. Book your demo here..

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular